PI3-Kinase pathway molecular targets

The phosophoinositide-3-kinase (PI3K) pathway is a hot area in cancer new product development and is currently attracting a lot of interest in drug development.

Infinity Pharmaceuticals yesterday announced they would begin two Phase 1 trials of their small molecule (IPI-145), previously licensed from Intellikine, that inhibits PI3K delta and PI3K gamma.

A review by Sally Church of the top posts of the past year on Pharma Strategy Blog, showed that the most popular post was, you guessed it on:

PI3K: A hot topic in cancer research

Amongst the 640,000 reads of Pharma Strategy Blog this past year and a choice of over 900 posts, that is certainly quite an achievement.  Incidentally, No 9 in the list of top 10 posts for the year, was Sally’s Update on PI3K from ASCO.

The PI3-kinase or PI3K pathway is one of Sally’s favorites, and as she notes it “has been shown to play a major role in proliferation and survival in a wide variety of human cancers, thus making it a potential target for therapeutic intervention.

In addition to Infinity, an number of biotech and pharma companies are actively involved in clinical research that targets this pathway.

New data and further insights are expected at the forthcoming AACR-NCI-EORTC conference on Molecular Targets and Cancer Therapeutics in San Francisco.

, , , , , , , , , , , , , , , ,

error: Content is protected !!